静脉补液治疗新生儿高胆红素血症的疗效：一项随机对照研究的荟萃分析。

The efficacy of intravenous fluid supplementation for neonatal hyperbilirubinemia: a meta-analysis of randomized controlled studies.

机构信息

Department of Infectious Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Department of Geriatrics, The First Branch of First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

出版信息

J Matern Fetal Neonatal Med. 2021 Nov;34(21):3580-3585. doi: 10.1080/14767058.2019.1688295. Epub 2019 Nov 17.

DOI:10.1080/14767058.2019.1688295

PMID:31736410

Abstract

INTRODUCTION

The efficacy of intravenous fluid supplementation for neonatal hyperbilirubinemia remains controversial. We conduct a systematic review and meta-analysis to explore the influence of intravenous fluid supplementation on treatment efficacy of neonatal hyperbilirubinemia.

METHODS

We search PubMed, Embase, Web of Science, EBSCO, and Cochrane Library databases through June 2019 for randomized controlled trials (RCTs) assessing the efficacy of intravenous fluid supplementation for neonatal hyperbilirubinemia. This meta-analysis is performed using the random-effect model.

RESULTS

Six RCTs are included in the meta-analysis. Overall, compared with control group for neonatal hyperbilirubinemia, intravenous fluid supplementation is associated with decreased TSB at 8 h (std. MD = -0.82; 95% CI = -1.46 to -0.17; = .01), 12 h (std. MD = -0.46; 95% CI = -0.81 to -0.10; = .01), 24 h (std. MD = -0.47; 95% CI = -0.78 to -0.16; = .003) and 36 h (std. MD = -0.37; 95% CI = -0.73 to -0.02; = .04), as well as reduced incidence of exchange transfusion (RR = 0.29; 95% CI = 0.14-0.59; = .0006), but has no significant impact on duration of phototherapy (std. MD = -0.34; 95% CI = -0.88-0.21; = .22).

CONCLUSIONS

Intravenous fluid supplementation can provide additional benefits for the treatment of neonatal hyperbilirubinemia.

摘要

简介

静脉补液治疗新生儿高胆红素血症的疗效仍存在争议。我们进行了一项系统评价和荟萃分析，以探讨静脉补液对新生儿高胆红素血症治疗效果的影响。

方法

我们通过检索 PubMed、Embase、Web of Science、EBSCO 和 Cochrane Library 数据库，获取截至 2019 年 6 月评估静脉补液治疗新生儿高胆红素血症疗效的随机对照试验（RCT）。本荟萃分析采用随机效应模型进行。

结果

纳入 6 项 RCT 进行荟萃分析。总体而言，与新生儿高胆红素血症对照组相比，静脉补液组在 8 小时（标准均数差 [std. MD] = -0.82；95%置信区间 [CI] = -1.46 至 -0.17； =.01）、12 小时（std. MD = -0.46；95% CI = -0.81 至 -0.10； =.01）、24 小时（std. MD = -0.47；95% CI = -0.78 至 -0.16； =.003）和 36 小时（std. MD = -0.37；95% CI = -0.73 至 -0.02； =.04）时血清总胆红素（TSB）水平降低，换血治疗的发生率降低（RR = 0.29；95% CI = 0.14-0.59； =.0006），但对光疗持续时间无显著影响（std. MD = -0.34；95% CI = -0.88-0.21； =.22）。